CVSI · XBRL financial data

CV Sciences financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CVSI's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	24,429	20,048	—	—	—	—
Revenue from contracts with customers	24,429	20,048	16,205	16,004	15,705	13,789
Cost of revenue	13,420	11,432	10,655	8,919	8,537	7,037
Gross profit	11,009	8,616	5,550	7,085	7,168	6,752
Research and development	2,943	1,185	307	151	118	122
Selling, general and administrative	30,658	25,877	12,090	9,745	9,240	7,622
General and administrative	30,658	25,877	12,090	3,740	3,986	3,153
Total operating expenses	33,601	27,062	12,397	—	—	—
Operating income (loss)	(22,592)	(18,446)	(6,847)	3,360	(2,190)	(470)
Interest expense	—	38	600	—	212	517
Other income (expense)	—	—	(1,541)	(264)	(212)	(479)
Income tax expense (benefit)	(317)	(87)	(47)	(6)	(8)	9
Net income (loss)	(22,284)	(15,554)	(8,214)	3,102	(2,394)	(958)
Earnings per share, basic USD per share	(0.22)	(0.14)	(0.07)	0.02	(0.01)	(0.01)
Earnings per share, diluted USD per share	(0.22)	(0.14)	(0.07)	0.02	(0.01)	(0.01)
Weighted average shares, basic thousands of shares	99,913	107,817	138,034	153,954	175,585	184,264
Weighted average shares, diluted thousands of shares	99,913	107,817	138,034	153,955	175,585	184,264

Fiscal years (CVSI's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	4,024	1,375	611	1,317	454	278
Accounts receivable	1,126	2,041	766	431	522	402
Inventory	8,840	8,624	6,563	5,655	4,897	4,087
Prepaid and other current assets	2,372	2,146	3,190	535	370	366
Total current assets	16,863	14,186	11,130	7,938	6,243	5,133
Property and equipment, net	2,877	1,717	575	379	399	344
Right-of-use asset	3,057	0	275	167	94	347
Goodwill	2,788	0	0	342	971	1,015
Total assets	30,625	18,066	12,736	9,200	7,927	6,962
Accounts payable	1,677	2,624	2,284	2,309	1,925	1,044
Accrued liabilities	9,805	10,915	9,690	3,422	3,424	2,447
Current portion of long-term debt	2,174	310	—	—	677	1,262
Total current liabilities	14,336	14,461	13,314	6,115	6,109	5,000
Long-term debt	1,453	0	—	—	0	387
Lease liability, non-current	3,467	0	188	58	19	100
Total liabilities	19,413	14,523	13,513	6,297	6,132	5,494
Accumulated deficit	(63,921)	(79,475)	(87,689)	(84,587)	(86,981)	(87,939)
Total stockholders' equity	11,212	3,543	(777)	2,903	1,795	1,468
Total liabilities and equity	30,625	18,066	12,736	9,200	7,927	6,962
Common shares outstanding (cover page) thousands of shares	106,606	122,570	152,105	163,228	184,264	193,458

Fiscal years (CVSI's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(22,284)	(15,554)	(8,214)	3,102	(2,394)	(958)
Stock-based compensation	3,881	3,210	1,009	218	258	497
Depreciation and amortization	872	1,153	992	235	334	192
Net cash from operating activities	(7,300)	(7,485)	(1,885)	2,253	(861)	(407)
Purchases of property and equipment	1,057	35	0	0	18	109
Net cash from investing activities	(1,057)	(35)	0	(156)	(28)	(109)
Proceeds from issuing common stock	193	4,407	0	—	—	—
Net cash from financing activities	3,274	4,370	1,121	(1,391)	32	337
Net change in cash	(5,083)	(3,150)	(764)	706	(863)	(176)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.
A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
CV Sciences	266	2,985	20*	225.8M	—	Q2 FY26 10-QJun 30, 2026
Minerva Neurosciences	24,652	not reported	(13,345)*	47.7M	5.6 quarters	Q2 FY26 10-QJun 30, 2026
Neuphoria Therapeutics	19,866	year only	1,214*	5.4M	—	Q4 FY26 10-KJun 30, 2026
Sunshine Biopharma	13,748	9,264	(918)*	3.9M	15.0 quarters	Q2 FY26 10-QJun 30, 2026
Zeo ScientifiX	2,265	not reported	not reported	7.8M	—	Q4 FY26 10-KTJun 30, 2026
Bolt Biotherapeutics	12,860	5	(6,540)*	1.9M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
Protagenic Therapeutics, Inc.\new	566	not reported	(944)	1.8M	0.6 quarters	Q1 FY26 10-QJun 30, 2026
Intensity Therapeutics	9,529	not reported	(2,340)*	3.3M	4.1 quarters	Q2 FY26 10-QJun 30, 2026
Biomerica	2,733	1,265	(802)	4.6M	3.4 quarters	Q1 FY27 10-QAug 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.